Compare Ecopetrol SA (EC) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Eli Lilly And Co — how do they compare? Ecopetrol SA trades at $16.93 (market cap $33.11B), while Eli Lilly And Co trades at $1,164.15 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 31.4× Ecopetrol SA's market cap, and Ecopetrol SA pays the higher dividend (3.83%). Which is the better fit depends on your goals — on Pluang, investors hold Ecopetrol SA for 84 Days and Eli Lilly And Co for 93 Days on average.
| EC | LLY | |
|---|---|---|
Market Cap | $33.11B | $1.04T |
Volume | 993,598 | 3,064,878 |
Sector | Energy | Health |
52-Week High | $18.26 | $1.28K |
52-Week Low | $8.61 | $799.57 |
Typical Hold Time | 84 Days | 93 Days |
Enterprise Value | $61.36B | $1.09T |
Dividend Yield | 3.83% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $16.63, down 1.95% with bearish technical signals. The stock shows attractive valuation metrics with P/E of 7.99 and EV/EBITDA of 4.04, but faces declining revenue from $159.6B in 2022 to $119.7B in 2025. Recent management changes and board restructuring under Colombia's new government create uncertainty, while the company maintains solid profitability with 11.37% net margin and 17.67% ROE.
EC presents a mixed outlook with undervalued fundamentals against operational challenges. Investment opportunity lies in discounted valuation and potential stabilization under new leadership, but risks include persistent revenue decline, political interference, and negative cash flow trends. Analyst consensus remains cautious with 54.55% hold rating and $16.85 price target, slightly above current levels.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.
Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
